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t is currently estimated that some 43 million Americans have hypertension. 1 This does not include another 7 million who were told they were hypertensive but were not taking antihypertensive medication and did not have elevated blood pressure when screened. Part 2 of the Third National Health and Nutrition Survey, which evaluated hypertension management from 1991 to 1994, contains disappointing news. 2 Fewer Americans with hypertension were being treated then than were treated in the period from 1988 to 1991 (53% v 55%). And, despite all that has been learned about the benefits of treating hypertension, current estimates are that only 27% of Americans with hypertension between the ages of 18 and 74 years have blood pressure readings Ͻ 140/90 mm Hg, the current goal recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). 2 Of those Ͼ 65 years of age, the control rates are even worse. The Kaiser group in Portland has estimated that only 7% of the elderly population with hypertension (Ն 65 years of age) have blood pressure readings Ͻ 140/90 mm Hg. 3 Because hypertension remains the most common disease-related reason that Americans see a physician and is a major antecedent for cardiovascular disease, it behooves us to examine why control rates are so dismal and to recommend steps to improve the situation.
MAKING THE DIAGNOSIS AND ESTABLISHING RISK
The diagnosis of hypertension still depends on demonstrating elevated blood pressure readings in the physician's office. 2 Proper technique must be used when taking the measurement, and most authorities would require at least two or three sets of elevated readings before diagnosing an individual as hypertensive. Hypertension is considered to be present if the systolic blood pressure is Ն 140 mm Hg, the diastolic blood pressure is Ն 90 mm Hg, or both. Those with a systolic blood pressure of 130 to 139 mm Hg or a diastolic blood pressure of 85 to 89 mm Hg are classified as having high normal blood pressure. 2 The same levels are used regardless of age, because we have learned that the risk imparted by an elevated blood pressure in older persons is equal to, if not greater than, that in younger persons. It is not appropriate to make any distinction in the definition of hypertension based on advancing age. Different cutoff points are used in children and adolescents. 4 In individuals without evidence of target organ damage who claim always to have normal blood pressure measurements outside of the physician's office, the diagnosis of "white coat" hypertension should be entertained, and home readings or ambulatory blood pressure measurements may be appropriate. 2, 5 If these readings are indeed within the normal range for the home or ambulatory setting, careful follow-up may be all that is needed.
EVALUATION
In most individuals with hypertension, a limited evaluation is all that is recommended. The history and physical examination should assess target organ damage and other cardiovascular risk factors, as well as conditions that might help guide the choice of therapy. For example, all individuals with hypertension should be asked specifically whether they have a family history of premature cardiovascular disease (myocardial infarction, cerebrovascular accident, or other cardiovascular disease before age 55 years in male relatives and before age 65 years in female relatives). All patients should be asked if they have asthma, gout, or diabetes, and they should be questioned systematically and scrupulously about whether they have had symptoms suggestive of heart failure or atherosclerosis (claudication, transient cerebral ischemia, or angina). A careful lifestyle history is imperative to establish whether the patient has any dietary habits that may need alteration (eg, too much dietary sodium or saturated fat, or too little potassium or calcium). Is the patient sedentary or excessively stressed? Does he or she drink too much alcohol? There is no purpose in spending time and energy recommending lifestyle modifications to a patient who already has a healthy lifestyle. The clinician must also establish whether the patient takes any other medications (either prescription or over-the-counter) that might interact with or counteract the benefits of the antihypertensive agents that may need to be prescribed. Finally, the clinician must carefully ascertain whether the patient has been previously treated for hypertension and what his or her experience was with those treatments.
CLASSIFICATION AND STRATIFICATION OF THE PATIENT WITH HYPERTENSION
The purpose of properly classifying and stratifying each patient with hypertension is to ensure that the right treatment, either lifestyle modification alone or in combination with drug therapy, can be selected for each individual. One of the most important innovations in JNC VI was the recommendation that therapy for hypertension be based on a risk assessment that includes both relative risk (blood pressure stage) and absolute risk (risk group). 2 Patients with hypertension are classified and stratified according to their level of blood pressure and whether there is evidence of other cardiovascular risk factors or target organ damage. Treatment recommendations are based on the category into which each patient falls (Table 1) . Whereas all patients with hypertension should unambiguously and vigorously be encouraged to lose weight if obese, limit alcohol intake to no more than two drinks per day, limit sodium intake to Յ 6 g of salt per day, become more active if sedentary, and follow other healthy lifestyle habits, JNC VI recognized that for those with 
SELECTING DRUG THERAPY
As with JNC V in 1993, JNC VI recommended that diuretics or ␤-blockers (for those Ͻ 60 years of age) be used for initial treatment in uncomplicated hypertension. 2, 8 This recommendation was based on the totality of evidence that regimens that began with these agents prevent morbidity and mortality. "Uncomplicated" means there are no indications for another class of drug. In certain populations, these recommendations are modified. In the elderly, for example, JNC VI followed the suggestion of the Working Party on the Elderly that "thiazide diuretics or ␤-blockers in combination with thiazide diuretics" should be used. 2, 9 For patients with hypertension who have such conditions as heart failure, type 1 diabetes with proteinuria, or myocardial infarction, JNC VI felt that these were compelling indications for recommending a different initial choice of treatment (Table 2 ). For those with heart failure, angiotensin-converting enzyme (ACE) inhibitors and diuretics should be used; for those with type 1 diabetes and proteinuria, ACE inhibitors are indicated; and for those recovering from a myocardial infarction, a ␤-blocker without intrinsic sympathomimetic activity or an ACE inhibitor (if there is systolic dysfunction) should be the initial treatment. In every instance, the choice would be altered if there were a contraindication to that class of agents. In older persons with isolated systolic hypertension, thiazide-like diuretics have been proved to reduce morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP). 10 Recently, a regimen beginning with a moderately long-acting calcium antagonist, nitrendipine, followed by an ACE inhibitor, enalapril, and finally a thiazide showed results very similar to those of SHEP. 11 Because of this, JNC VI included long-acting dihydropyridines as a compelling indication for treating isolated systolic hypertension in older persons, but preferred diuretics because of much longer experience with those agents in this group and fewer concerns about long-term safety.
JNC VI also suggested that there were clinical scenarios in which neither of these recommendations was appropriate and that the clinician should use clinical judgment in making a selection ( Table 2 ). In situations in which the choice of either a thiazide or a ␤-blocker would have an unfavorable effect on a coexisting comorbid condition, any one of five classes of other agents-␣-blockers, combined ␣-blockers and ␤-blockers, ACE inhibitors, angiotensin receptor blockers (ARB), or calcium antagonists-could be substituted. There are also situations in which another coexisting condition would alter the initial choice of therapy. For example, a person with benign prostatic hypertrophy might specifically benefit from treatment with an ␣-blocker, and one with heart failure who had experienced a cough with an ACE inhibitor might benefit from treatment with losartan or with carvedilol. 12, 13 JNC VI recommended starting treatment with the lowest available dose or a once-daily medication and titrating to goal (Ͻ 140 mmHg for systolic blood pressure and Ͻ 90 mmHg for diastolic blood pressure unless diabetes mellitus or chronic renal disease and Ն 1 g of proteinuria are present, in which case lower goals are appropriate). If the goal is not achieved, a second drug should be added if the patient with hypertension has a partial response (blood pressure was lowered but not to goal). If not, the treatment should be changed, but only if there was no response or there were intolerable side effects. If blood pressure is not at goal after the full doses of two medications, the patient should be considered to have refractory hypertension, and either additional therapy should be added or the patient should be referred to a hypertension specialist for further evaluation or therapy. 14 JNC VI recognized the value of low-dose, fixed-dose combinations and considered them a reasonable alternative for initial treatment in selected patients.
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WHY HAVE WE NOT DONE BETTER?
With all the effective antihypertensive agents and combinations available, it is surprising that we are still controlling blood pressure to goal in only a small minority of patients with hypertension. There are a number of reasons that may explain our failure to do better.
Adverse Reactions When treating patients who have no symptoms referable to their condition and who are likely not to notice any specific clinical benefit from therapy, it is particularly critical that the regimen used be as free of side effects as possible. As our approach to the treatment of hypertension has evolved, we have progressed from using drugs that are less specific for the pathophysiologic abnormality we are modifying to those that are more specific and associated with fewer adverse reactions. For example, we have long understood the role of the central and peripheral nervous systems in the pathogenesis of hypertension. Early drugs such as ganglionic blockers lowered blood pressure effectively, but were very poorly tolerated. In time, central ␣ 2 agonists, such as ␣-methyldopa and clonidine, were developed. These drugs had a much better side effect profile but were still often unacceptable to many patients. Finally, agents that specifically blocked ␣ and ␤ receptors were manufactured. Such drugs lowered blood pressure with few, if any, of the side effects noted with lessspecific agents (Figure 1) . Similarly, we have progressed from poorly tolerated direct-acting vasodilators to much better tolerated calcium antagonists, to reduce the excessive vasoconstriction present in most hypertensive patients. With the development of 
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agents that block the renin-angiotensin-aldosterone system, another important physiologic system that is often abnormally regulated in persons with hypertension, early attempts to interfere with the renin cascade (with saralasin or even with ␤-blockers) did lower blood pressure, but often with too many adverse reactions. ACE inhibitors, being more specific, improved the side effect profile but had a significant number of adverse reactions of their own (cough and angioedema in particular), probably resulting from effects on other enzyme systems and substrates. Currently, ARB, which directly block attachment of angiotensin II to the AT 1 receptor, reduce blood pressure as effectively as do ACE inhibitors, but without the disturbing side effects.
Patient Issues
Patients with hypertension must take some responsibility for our less-than-acceptable national record for treating this condition. Adherence to antihypertensive therapy in primary care settings is often Ͻ 50%. Poor adherence to weight loss regimens, sodium restriction, and exercise programs certainly plays a role. However, we must never fail to realize that inadequate blood pressure control and nonadherence to medication regimens and to a healthy lifestyle cannot be blamed on our patients. We must take responsibility for their care and for educating them about their condition.
Physician Issues JNC VI has provided us with guidance on how to care for patients with hypertension in ways that will tend to improve adherence to an antihypertensive regimen (Table 3) . These recommendations challenge us to use our common sense. We must always consider medication nonadherence when a patient with hypertension is not at goal and be certain to maintain contact with our patients, especially when they miss an appointment. Missed appointments and nonadherence to medication regimens often go together. We must provide adequate education about hypertension and its consequences, and we must be open to adjusting our approach if a patient's hypertension is not controlled to goal.
Go for Goal
If there is one overriding message from the treatment recommendations of JNC VI and from 2 the data on which they were based, it is that we should select a goal (Ͻ 140 mm Hg and Ͻ 90 mm Hg, and even lower for patients with diabetes and those with renal disease and proteinuria) and not settle for less. The HOT study and a recent analysis of preliminary data from the Antihypertensive and Lipid Lowering Trial to Prevent Heart Attack (ALLHAT) show that we can reach that goal in the majority of patients with hypertension. 6, 16 In HOT, 86% of patients were treated to Ͻ 90 mm Hg and maintained at that level for Ͼ 3 years, using a regimen beginning with a dihydropyridine calcium antagonist at a low dose, followed by either an ACE inhibitor or a ␤-blocker, also at low dose. In ALLHAT, one of four regimens (diuretics, ACE inhibitors, dihydropyridine calcium antagonists, or ␣-blockers) was successful at lowering blood pressure to Ͻ 140 mm Hg and Ͻ 90 mm Hg in 55% of the subjects at 28 months. 16 In both of these effectiveness studies, patients were treated primarily by practitioners in their offices, not by clinical trials specialists in academic centers. 17 Practicing physicians can do it, if a goal is set and adhered to.
CONCLUSION
Although we have made considerable progress in the past several decades in reducing heart disease and stroke by treating hypertension, much remains to be done. The use of better-tolerated antihypertensives, a better appreciation of how to treat an asymptomatic chronic condition and how to keep patients adhering to treatment, and aiming for a defined goal will all greatly improve our success rates. Better blood pressure control is quite likely to enhance our primary goal of reducing heart disease and stroke as much as we can. Our concern has been heightened of late, as we realize that stroke rates in the United States have ceased to decline and may actually be starting to rise. 2 If we do anything well when we treat hypertension, it is to reduce the risk of stroke. Proper management of this risk factor along with proper management of other modifiable risk factors not only will increase life span, but will also very likely improve the quality of life in later years. 18 Such an objective is well within our reach.
